Last reviewed · How we verify
Physician's Choice SOC
Physician's Choice SOC is an X-ray activated photodynamic therapy agent that generates reactive oxygen species upon X-ray irradiation to destroy cancer cells.
Physician's Choice SOC is an X-ray activated photodynamic therapy agent that generates reactive oxygen species upon X-ray irradiation to destroy cancer cells. Used for Locally advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | Physician's Choice SOC |
|---|---|
| Sponsor | Rakuten Medical, Inc. |
| Drug class | X-ray activated photodynamic therapy agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is a scintillator-based photodynamic therapy (PDT) approach developed by Rakuten Medical that combines a photosensitizing agent with X-ray activation. Upon X-ray exposure, the agent emits light that activates the photosensitizer to produce singlet oxygen and reactive oxygen species, inducing localized tumor cell death. This mechanism allows deep tissue penetration compared to traditional light-based PDT.
Approved indications
- Locally advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Skin photosensitivity
- Local tissue irritation at treatment site
- Fatigue
Key clinical trials
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease (PHASE2)
- A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PHASE2)
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (PHASE3)
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (PHASE2, PHASE3)
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases (PHASE3)
- WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (PHASE2)
- Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (PHASE2)
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician's Choice SOC CI brief — competitive landscape report
- Physician's Choice SOC updates RSS · CI watch RSS
- Rakuten Medical, Inc. portfolio CI